El BPC-157 es un péptido sintético, una copia hecha en laboratorio de un fragmento de una proteína presente en el jugo gástrico, que se vende en internet para curar tendones, ligamentos y el intestino. Casi toda la evidencia que respalda esos usos procede de estudios en ratas y otros animales y de células en placa. En esos modelos acelera la curación de tendones, ligamentos y músculos seccionados y de lesiones intestinales, y favorece el crecimiento de nuevos vasos sanguíneos. Ningún ensayo adecuado en humanos ha probado si hace algo de esto en personas.
No es un medicamento aprobado en ningún lugar. Se vende como un producto químico de investigación, al margen de los controles farmacéuticos. Lo que hay en un vial dado a menudo no está verificado, y su seguridad a largo plazo en personas es desconocida. Está prohibido en el deporte de competición.
Findings & Outcomes
What It Is
BPC-157 stands for Body Protection Compound 157. It is a chain of fifteen amino acids, a pentadecapeptide, and its sequence copies part of a larger protective protein identified in human gastric juice. It is made in a laboratory, and researchers have studied this synthesized fragment since the 1990s. It resists stomach acid, which is unusual for a peptide.
It is sold online as a capsule, an oral liquid, or a powder for injection, for a long list of uses: healing tendons, ligaments, and muscle after injury, easing joint and tendon pain, healing the gut lining, and recovering faster from surgery. Almost all of the support for those uses comes from animal experiments and cell studies. It reaches buyers as a research chemical sold for laboratory use.
Anatomy
1The peptide
BPC-157 is a short synthetic peptide of fifteen amino acids. Its sequence copies a stretch of a larger protein found in human gastric juice, the fluid that protects and repairs the stomach lining. The lab-made fragment is what is studied and sold; the full natural protein it copies part of is a different molecule. Because it survives stomach acid, sellers argue it can work as a pill you swallow. That is their main case for an oral form.
2The forms sold
It is sold as oral capsules and liquids, and as a powder that buyers reconstitute and inject under the skin or near an injured tendon or joint. Most of the marketing centers on the injectable form.
What It Does
Researchers gave BPC-157 to rats and mice with surgically created injuries, by injection and in drinking water, then measured the repair. The animal doses give no guide to a human amount. In rats it speeds the healing of a surgically cut Achilles tendon and improves the recovery of movement afterward. In the same model it improves the healing of a cut knee ligament and of crushed muscle. In rat models of gut injury it heals lesions and closes fistulas, the abnormal channels that form between the bowel and nearby organs.
The animal healing signal is consistent across many studies, though it comes from a small number of laboratories, and it is the reason BPC-157 is sold. These results have not been reproduced in any human trial.
A healed wound in a rat means only that the effect may be worth testing in people; it proves nothing about people on its own.
A compound can act differently in a person than in an animal, and it can even do the opposite, or have a much larger or smaller effect.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
El BPC-157 es un pentadecapéptido sintético derivado de una proteína del jugo gástrico, estable en el ácido estomacal
El BPC-157 es una copia hecha en laboratorio de un pequeño fragmento de una proteína encontrada en el jugo gástrico. Sobrevive al ácido estomacal, lo cual es inusual para un péptido. Las revisiones describen lo que hace en animales y células; no es la proteína natural y no es un medicamento aprobado.
El BPC-157 (Body Protection Compound 157) es un pentadecapéptido gástrico estable, una secuencia parcial sintetizada de una proteína encontrada en el jugo gástrico humano. Los artículos de revisión lo caracterizan como un mediador citoprotector con efectos sobre el tracto gastrointestinal y el sistema vascular observados en muchos experimentos preclínicos. Estos son resúmenes de revisión de trabajo en animales y células, no datos de resultados humanos.
Who this may not transfer to:This is a description of the compound and its preclinical characterization, not a measurement in people, so it conveys what BPC-157 is, not an effect size that transfers to any group.
The study · 1
Sikiric et al., Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing · Curr Pharm Des 2018;24(18):1990-2001
El BPC-157 promueve el crecimiento de nuevos vasos sanguíneos a través de VEGFR2 en estudios celulares y animales
En células cultivadas en una placa y en animales, el BPC-157 ayudó a formar nuevos vasos sanguíneos al activar un receptor llamado VEGFR2. El nuevo suministro sanguíneo es parte de cómo se repara cualquier tejido, que es la razón propuesta por la que podría acelerar la cicatrización. Esta es una observación de laboratorio, no un beneficio demostrado en una persona.
Hsieh y colaboradores (2017) reportaron que la actividad proangiogénica del BPC-157 se asoció con la activación y regulación al alza de VEGFR2 (receptor 2 del VEGF) en células endoteliales vasculares, con efectos de apoyo sobre la formación de tubos endoteliales y el crecimiento de vasos. Este es un estudio de mecanismo a nivel celular y animal; describe una vía plausible hacia la reparación de tejidos pero no mide la cicatrización en humanos.
Who this may not transfer to:Measured in cultured endothelial cells and animals. The angiogenic mechanism is a laboratory finding, and whether it produces any benefit in a person was not tested.
The study · 1
Hsieh et al., Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation · J Mol Med (Berl) 2017;95(3):323-333
El BPC-157 aceleró la cicatrización de un tendón de Aquiles cortado quirúrgicamente en ratas
En ratas con un tendón de Aquiles cortado quirúrgicamente, el BPC-157 ayudó al tendón a sanar y los animales recuperaron el movimiento antes. Este es un estudio animal; no se ha demostrado que sane tendones en personas.
Krivic y colaboradores (2008) seccionaron la unidad tendón-hueso de Aquiles en ratas y encontraron que el BPC-157 mejoró la recuperación funcional temprana, en un modelo también usado para compararlo con el corticoide metilprednisolona. Un trabajo relacionado en ratas de Chang y colaboradores (2011) reportó que el BPC-157 promovió la cicatrización del tendón con un aumento del crecimiento, supervivencia y migración de los fibroblastos tendinosos. Estos son hallazgos animales y celulares consistentes; ningún ensayo humano ha probado la cicatrización de tendones.
Who this may not transfer to:Measured in a rat tendon-transection model. The healing signal is an animal finding, and whether it occurs in a human tendon was not tested.
The study · 1
Krivic et al., Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone · Inflamm Res 2008;57(5):205-210
El BPC-157 mejoró la cicatrización de ligamentos en ratas
En ratas con un ligamento de rodilla cortado, el BPC-157 mejoró la cicatrización. Este es un estudio animal, y el mismo efecto no se ha demostrado en personas.
Cerovecki y colaboradores (2010) seccionaron el ligamento colateral medial en ratas y encontraron que el BPC-157 (estudiado bajo el código PL 14736) mejoró la cicatrización del ligamento en medidas funcionales, biomecánicas, macroscópicas y microscópicas. Este es un modelo animal controlado; no existe ningún ensayo humano de BPC-157 para lesiones ligamentosas.
Who this may not transfer to:Measured in a rat ligament-transection model. The healing effect is an animal finding, and whether it occurs in a human ligament was not tested.
The study · 1
Cerovecki et al., Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat · J Orthop Res 2010;28(9):1155-1161
El BPC-157 aceleró la recuperación de músculo aplastado en ratas
En ratas con músculo aplastado, el BPC-157 ayudó al músculo a sanar y recuperar la función. Este es un estudio animal, y no se ha demostrado que funcione de la misma manera en personas.
Novinscak y colaboradores (2008) produjeron una lesión por aplastamiento del complejo del músculo gastrocnemio en ratas y encontraron que el BPC-157 mejoró la cicatrización y la recuperación funcional. Un trabajo relacionado en ratas de Staresinic y colaboradores (2006) reportó una terapia eficaz de un músculo cuádriceps seccionado. Estos son hallazgos animales consistentes; ningún ensayo humano ha probado la cicatrización muscular.
Who this may not transfer to:Measured in a rat muscle-crush model. The recovery signal is an animal finding, and whether it occurs in human muscle was not tested.
The study · 1
Novinscak et al., Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat · Surg Today 2008;38(8):716-725
El BPC-157 elevó la expresión del receptor de la hormona del crecimiento en células tendinosas cultivadas
En células tendinosas cultivadas en una placa, el BPC-157 elevó la cantidad del receptor de la hormona del crecimiento e hizo que las células se multiplicaran más. Esta es una vía propuesta por la cual podría acelerar la cicatrización de tendones. Es un hallazgo de laboratorio a nivel celular, no un beneficio demostrado en una persona.
Chang y colaboradores (2014) encontraron que el BPC-157 potenció la expresión del receptor de la hormona del crecimiento en fibroblastos tendinosos cultivados y aumentó la proliferación celular de manera dependiente de la dosis, lo cual los autores propusieron que podría sensibilizar a las células tendinosas a la hormona del crecimiento y apoyar la cicatrización del tendón. Este es un mecanismo in vitro; no mide la cicatrización del tendón en un animal o una persona.
Who this may not transfer to:Measured in cultured tendon cells. The receptor and proliferation changes are a laboratory mechanism, and whether they translate into healing in a person was not tested.
The study · 1
Chang et al., Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts · Molecules 2014;19(11):19066-19077
El BPC-157 relajó el tejido arterial humano aislado a través de la vía del óxido nítrico
En piezas de arteria humana estudiadas en una placa de laboratorio, el BPC-157 hizo que el vaso se relajara a través de la vía del óxido nítrico, el sistema que ensancha los vasos sanguíneos. Esta es evidencia en tejido aislado sobre cómo actúa sobre los vasos sanguíneos, no un efecto medido en una persona viva.
Yildirim y colaboradores (2026) probaron el BPC-157 en segmentos aislados de arteria mamaria interna humana y encontraron un efecto vasorrelajante dependiente del endotelio mediado por óxido nítrico. Esto añade respaldo en tejido humano para la interacción del péptido con el sistema del óxido nítrico, una vía repetidamente implicada en sus efectos en animales. Es un estudio de tejido ex vivo, no una medición de ningún resultado en una persona viva.
Who this may not transfer to:Measured in isolated human artery tissue in the laboratory. The vasorelaxant mechanism describes how BPC-157 acts on vessels and is not an outcome measured in a living person.
The study · 1
Yildirim et al., Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery · J Clin Med 2026;15(9)
Digestion
El BPC-157 sanó lesiones intestinales y cerró una fístula en ratas
En ratas con un canal anormal entre el intestino y la vejiga, el BPC-157 ayudó a que el canal se cerrara y el tejido sanara. Ha sanado lesiones intestinales en varios modelos de rata. Nada de esto se ha probado en personas.
Grgic y colaboradores (2016) encontraron que el BPC-157 sanó la fístula colovesical en ratas, mejorando el cierre y la cicatrización del tejido. Esto se sitúa entre muchos estudios en ratas de BPC-157 en lesión gastrointestinal y modelos de enfermedad inflamatoria intestinal revisados por Sikiric y colaboradores. La evidencia de cicatrización intestinal es consistente entre modelos animales de un pequeño número de laboratorios; no existe un ensayo humano adecuado para la enfermedad inflamatoria intestinal ni para ninguna afección gastrointestinal.
Who this may not transfer to:Measured in a rat fistula model. The gut-healing signal is an animal finding, and whether it occurs in the human gut was not tested.
The study · 1
Grgic et al., Stable gastric pentadecapeptide BPC 157 heals rat colovesical fistula · Eur J Pharmacol 2016;780:1-7
How It Works
The mechanism described most often is angiogenesis, the growth of new blood vessels, which is part of how a tendon, ligament, or gut wall repairs. In cultured blood-vessel cells and in animals, BPC-157 promotes angiogenesis, an effect linked to activation of VEGFR2, the receptor for the main blood-vessel growth signal. That behavior appears in cultured cells; whether it heals tissue in a person is untested.
BPC-157 also interacts with the nitric oxide system, the signaling pathway that relaxes blood vessels and regulates blood flow. In human artery tissue in the lab, it made the vessel relax and widen, working through the cells that line the vessel wall. In cultured tendon cells it raised the expression of the growth hormone receptor and increased cell growth, one proposed route to faster tendon repair.
How To Think About It
How To Think About It
The healing people want from BPC-157 is best reached by the routes with human evidence behind them. The consistent tendon- and gut-healing signal in animals is a real reason the peptide is being watched. It is a legitimate target for the human trials that have not yet been run.
Tendons and muscle repair with graded loading and time. Human trials support progressive rehabilitation as the best-evidenced lever for tendon and muscle recovery.
Adequate protein supplies the building blocks for repair, and sleep is when much of that repair occurs. Both are supported by human evidence for recovery.
Go Deeper
- Peptides: the wider category BPC-157 belongs to, and how to keep the few approved peptide drugs apart from the many unregulated ones.
- TB-500: the sibling healing peptide sold the same way, with the same shape of evidence, rodent research and no completed human trial.
- Growth hormone secretagogues: the other frontier peptides sold for muscle and recovery, where the same rule about moving a marker versus changing an outcome applies.
- Resistance training: the loading that repairs and strengthens tendon and muscle, with human evidence behind it.
- Protein and muscle: what to eat to give repair its building blocks, the food-first side of recovery.
The Chinese Medicine View
No classical Chinese text describes BPC-157, a molecule synthesized in the last few decades. The tradition still offers a lens on the injury itself. Chinese medicine holds that the Spleen governs the muscles and flesh, the Liver governs the sinews, meaning the tendons and ligaments, and the Kidney governs the bones. It treats the repair of an injury as the work of Qi and Blood closing the wound. A slow-healing wound reads as a deficiency of Qi and Blood, or as stagnation blocking their flow.
The classical approach to a slow wound supports the person's own capacity to heal with herbs, food, and rest, and it does not add a single isolated agent. Here the tradition offers a caution. Building the body up helps someone who is genuinely depleted and can take in the support. Pushing a system that cannot use it only wears it down further.
Cautions
Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
La base de evidencia del BPC-157 es preclínica, sin un ensayo humano adecuado de eficacia o seguridad
Seiwerth y colaboradores (2021) revisaron la evidencia de cicatrización de heridas para el BPC-157 y describen una gran literatura preclínica en animales y células, sin un ensayo humano aleatorizado adecuado que establezca eficacia o seguridad a largo plazo. La consistencia de la señal animal, en muchos estudios de un pequeño número de laboratorios, es la razón del interés continuado, pero el caso humano sigue sin probarse.Seiwerth et al., Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
Sold as an unregulated research chemical
BPC-157 reaches buyers as a research chemical, with no pharmaceutical oversight, so no authority verifies its identity, dose, purity, or sterility. Testing of gray-market peptides has found wrong doses, missing active ingredient, and contamination. The injectable form adds the risk of self-injecting a nonsterile product. In the United States the FDA has flagged BPC-157 as lacking the safety data needed for pharmacy compounding.
Human safety is unknown
The safety of BPC-157 in people, including its long-term safety, has not been established. No reports of harm are not the same as proof it is safe; that only means almost no one has been studied. Anyone considering it is acting on animal data and personal reports, without the human safety record an approved medicine has.
The angiogenesis and cancer question is open
The same growth of new blood vessels that could help a wound heal is also part of how tumors grow. No long human study has looked at whether promoting angiogenesis with this peptide affects cancer risk. This concern is unconfirmed, but it is a real reason for caution in anyone with a personal or family history of cancer.
Banned in competitive sport
BPC-157 is prohibited by the World Anti-Doping Agency, which lists it among non-approved substances banned at all times. Any athlete subject to drug testing who uses it risks a sanction, and this holds whether it is taken by mouth or injected.
No data in pregnancy, breastfeeding, or children
BPC-157 has not been studied in pregnancy, breastfeeding, or children, so there is no basis for judging it safe in any of them. With no human data at all, avoiding it in these groups is the only defensible position.
A persistent injury needs a diagnosis
Persistent or severe pain, a tendon or muscle that is not recovering, or gut symptoms can signal a problem that needs a specific treatment. Self-treating with an experimental substance can delay that diagnosis. A clinician or physical therapist who can identify what is wrong is the step for a real injury.
Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.
Common Questions
Does BPC-157 actually heal tendons and injuries?
In rat studies, BPC-157 speeds tendon, ligament, and muscle repair and restores movement, and those results are consistent across many labs. In people, none of this has been shown. No trial in people has tested it for tendon, ligament, muscle, or joint injury, so the healing claims made for it online rest on animal data.
Is BPC-157 safe?
Its safety in people is unknown, because almost no one has been studied. Short-term and long-term effects in humans have not been measured. It is also sold as an unregulated research chemical, so its actual contents are often unverified. The new blood vessels it promotes raise an open question about cancer.
Is BPC-157 legal or approved?
It is not approved as a medicine in any country. It is sold as a research chemical, marketed for laboratory use, which is how it reaches buyers without going through drug approval. In the United States the FDA has said BPC-157 lacks the safety data required for pharmacy compounding. It is also banned in competitive sport by the World Anti-Doping Agency.
Is the oral or the injectable form better?
Neither has been shown to work in people, so there is no evidence-based answer. Animal studies have used both oral and injected routes. The injectable form is the one most marketed, and it adds the risks of injecting an unsterile, unverified product. Without a human trial, any choice between the two rests on animal data.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 9 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.